{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-191273","form_type":"8-K/A","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.827634+00:00","generated_at":"2026-05-17T09:25:14.123604+00:00","sec_items":["9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst settles FIRDAPSE patent suit with Lupin; generic entry delayed to Feb 2035","bullets":["Lupin receives license to market generic FIRDAPSE no earlier than February 25, 2035, if FDA-approved.","All pending patent litigation between Catalyst/SERB and Lupin will be terminated.","Previous settlements reached with Teva Pharmaceuticals and Inventia Healthcare Limited.","Ongoing FIRDAPSE patent litigation against Hetero remains active.","Confidential settlement agreement to be submitted to FTC and DOJ for review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-191273","json":"https://secwatch.observer/filing/0001193125-25-191273.json","markdown":"https://secwatch.observer/filing/0001193125-25-191273.md","text":"https://secwatch.observer/filing/0001193125-25-191273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/0001193125-25-191273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/d40349d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:25:14.123604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}